PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of iaiPermissionsJournals.ASM.orgJournalIAI ArticleJournal InfoAuthorsReviewers
 
Infect Immun. 1997 December; 65(12): 5171–5175.
PMCID: PMC175745

Passive protection by polyclonal antibodies against Bacillus anthracis infection in guinea pigs.

Abstract

The protective effects of polyclonal antisera produced by injecting guinea pigs with protective antigen (PA), the chemical anthrax vaccine AVA, or Sterne spore vaccine, as well as those of toxin-neutralizing monoclonal antibodies (MAbs) produced against PA, lethal factor, and edema factor, were examined in animals infected with Bacillus anthracis spores. Only the anti-PA polyclonal serum significantly protected the guinea pigs from death, with 67% of infected animals surviving. Although none of the MAbs was protective, one PA MAb caused a significant delay in time to death. Our findings demonstrate that antibodies produced against only PA can provide passive protection against anthrax infection in guinea pigs.

Full Text

The Full Text of this article is available as a PDF (149K).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • BEALL FA, TAYLOR MJ, THORNE CB. Rapid lethal effect in rats of a third component found upon fractionating the toxin of Bacillus anthracis. J Bacteriol. 1962 Jun;83:1274–1280. [PMC free article] [PubMed]
  • BELTON FC, STRANGE RE. Studies on a protective antigen produced in vitro from Bacillus anthracis: medium and methods of production. Br J Exp Pathol. 1954 Apr;35(2):144–152. [PubMed]
  • Fish DC, Mahlandt BG, Dobbs JP, Lincoln RE. Purification and properties of in vitro-produced anthrax toxin components. J Bacteriol. 1968 Mar;95(3):907–918. [PMC free article] [PubMed]
  • Friedlander AM. Macrophages are sensitive to anthrax lethal toxin through an acid-dependent process. J Biol Chem. 1986 Jun 5;261(16):7123–7126. [PubMed]
  • Gordon VM, Leppla SH, Hewlett EL. Inhibitors of receptor-mediated endocytosis block the entry of Bacillus anthracis adenylate cyclase toxin but not that of Bordetella pertussis adenylate cyclase toxin. Infect Immun. 1988 May;56(5):1066–1069. [PMC free article] [PubMed]
  • Green BD, Battisti L, Koehler TM, Thorne CB, Ivins BE. Demonstration of a capsule plasmid in Bacillus anthracis. Infect Immun. 1985 Aug;49(2):291–297. [PMC free article] [PubMed]
  • Hambleton P, Turnbull PC. Anthrax vaccine development: a continuing story. Adv Biotechnol Processes. 1990;13:105–122. [PubMed]
  • Hansen MB, Nielsen SE, Berg K. Re-examination and further development of a precise and rapid dye method for measuring cell growth/cell kill. J Immunol Methods. 1989 May 12;119(2):203–210. [PubMed]
  • HENDERSON DW, PEACOCK S, BELTON FC. Observations on the prophylaxis of experimental pulmonary anthrax in the monkey. J Hyg (Lond) 1956 Mar;54(1):28–36. [PMC free article] [PubMed]
  • Ivins BE, Welkos SL. Recent advances in the development of an improved, human anthrax vaccine. Eur J Epidemiol. 1988 Mar;4(1):12–19. [PubMed]
  • Ivins BE, Welkos SL, Little SF, Crumrine MH, Nelson GO. Immunization against anthrax with Bacillus anthracis protective antigen combined with adjuvants. Infect Immun. 1992 Feb;60(2):662–668. [PMC free article] [PubMed]
  • Ivins BE, Fellows PF, Nelson GO. Efficacy of a standard human anthrax vaccine against Bacillus anthracis spore challenge in guinea-pigs. Vaccine. 1994 Aug;12(10):872–874. [PubMed]
  • KLEIN F, HODGES DR, MAHLANDT BG, JONES WI, HAINES BW, LINCOLN RE. Anthrax toxin: causative agent in the death of rhesus monkeys. Science. 1962 Dec 21;138(3547):1331–1333. [PubMed]
  • Klimpel KR, Arora N, Leppla SH. Anthrax toxin lethal factor contains a zinc metalloprotease consensus sequence which is required for lethal toxin activity. Mol Microbiol. 1994 Sep;13(6):1093–1100. [PubMed]
  • Kochi SK, Schiavo G, Mock M, Montecucco C. Zinc content of the Bacillus anthracis lethal factor. FEMS Microbiol Lett. 1994 Dec 15;124(3):343–348. [PubMed]
  • Leppla SH. Anthrax toxin edema factor: a bacterial adenylate cyclase that increases cyclic AMP concentrations of eukaryotic cells. Proc Natl Acad Sci U S A. 1982 May;79(10):3162–3166. [PubMed]
  • Little SF, Leppla SH, Cora E. Production and characterization of monoclonal antibodies to the protective antigen component of Bacillus anthracis toxin. Infect Immun. 1988 Jul;56(7):1807–1813. [PMC free article] [PubMed]
  • Little SF, Leppla SH, Friedlander AM. Production and characterization of monoclonal antibodies against the lethal factor component of Bacillus anthracis lethal toxin. Infect Immun. 1990 Jun;58(6):1606–1613. [PMC free article] [PubMed]
  • Little SF, Leppla SH, Burnett JW, Friedlander AM. Structure-function analysis of Bacillus anthracis edema factor by using monoclonal antibodies. Biochem Biophys Res Commun. 1994 Mar 15;199(2):676–682. [PubMed]
  • Little SF, Novak JM, Lowe JR, Leppla SH, Singh Y, Klimpel KR, Lidgerding BC, Friedlander AM. Characterization of lethal factor binding and cell receptor binding domains of protective antigen of Bacillus anthracis using monoclonal antibodies. Microbiology. 1996 Mar;142(Pt 3):707–715. [PubMed]
  • Mikesell P, Ivins BE, Ristroph JD, Dreier TM. Evidence for plasmid-mediated toxin production in Bacillus anthracis. Infect Immun. 1983 Jan;39(1):371–376. [PMC free article] [PubMed]
  • Sanchez A, Pifat DY, Kenyon RH, Peters CJ, McCormick JB, Kiley MP. Junin virus monoclonal antibodies: characterization and cross-reactivity with other arenaviruses. J Gen Virol. 1989 May;70(Pt 5):1125–1132. [PubMed]
  • SMITH H, KEPPIE J, STANLEY JL. The chemical basis of the virulence of Bacillus anthracis. V. The specific toxin produced by B. Anthracis in vivo. Br J Exp Pathol. 1955 Oct;36(5):460–472. [PubMed]
  • STANLEY JL, SMITH H. Purification of factor I and recognition of a third factor of the anthrax toxin. J Gen Microbiol. 1961 Sep;26:49–63. [PubMed]
  • Turnbull PC, Leppla SH, Broster MG, Quinn CP, Melling J. Antibodies to anthrax toxin in humans and guinea pigs and their relevance to protective immunity. Med Microbiol Immunol. 1988;177(5):293–303. [PubMed]
  • Uchida I, Sekizaki T, Hashimoto K, Terakado N. Association of the encapsulation of Bacillus anthracis with a 60 megadalton plasmid. J Gen Microbiol. 1985 Feb;131(2):363–367. [PubMed]
  • Welkos SL, Friedlander AM. Comparative safety and efficacy against Bacillus anthracis of protective antigen and live vaccines in mice. Microb Pathog. 1988 Aug;5(2):127–139. [PubMed]

Articles from Infection and Immunity are provided here courtesy of American Society for Microbiology (ASM)